mastocytosis

(redirected from Systemic mastocytosis)
Also found in: Dictionary, Medical.

mastocytosis

[¦mas·tə‚sī′tō·səs]
(medicine)
Excessive mast cell proliferation. Also known as mast-cell disease.
Mentioned in ?
References in periodicals archive ?
Valent, consultant in a global Novartis trial investigating the effects of midostaurin in patients with advanced systemic mastocytosis.
Metterlein, "Anaesthesia and orphan disease: rapid sequence induction in systemic mastocytosis," European Journal of Anaesthesiology, vol.
Fifty percent of patients with total serum tryptase levels between 20 and 75 ng/ml had evidence of systemic mastocytosis, whereas all patients with levels >75 ng/ml had proven systemic involvement.
Rydapt was also approved for adults with certain types of rare blood disorders (aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm or mast cell leukemia).
In fact, recent studies have shown that use of omalizumab gives positive results in many allergic diseases, mainly including asthma, atopic dermatitis, allergic rhinitis, latex allergy, chronic urticaria, nasal polyposis, systemic mastocytosis, and idiopathic allergy (3).
We therefore performed bone marrow biopsy which ruled out systemic mastocytosis.
Systemic mastocytosis is associated with 30% of hematological neoplasms [9], and thus, the classification of systemic mastocytosis with associated hematological neoplasm (SM-AHN) exists [10].
Systemic Mastocytosis, Hyperimmunoglobulin E Syndrome, and Eosinophilic Gastroenteritis.
Alternatively, systemic mastocytosis, where mast cells invade extracutaneous organs such as the bone marrow or the gastrointestinal tract, may present with or without associated skin lesions.
In contrast, Langerhans cell histiocytosis and systemic mastocytosis (SM) are myeloid neoplasms associated with secondary eosinophilia because the eosinophils appear to be reactive, rather than arising from a neoplastic clone.
MIDOSTAURIN COMPLETELY resolved at least one type of organ damage for 45% of patients with advanced systemic mastocytosis, in a multicenter, open-label, phase II, industry-sponsored trial.
[USPRwire, Mon Feb 01 2016] GlobalData's clinical trial report, "Systemic Mastocytosis Global Clinical Trials Review, H2, 2015" provides an overview of Systemic Mastocytosis clinical trials scenario.

Full browser ?